Useful Markers for Detecting Minimal Residual Disease in Cases of Neuroblastoma
نویسندگان
چکیده
منابع مشابه
Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers.
BACKGROUND PCR-based detection of minimal residual disease (MRD) in neuroblastoma (NB) patients can be used for initial staging and monitoring therapy response in bone marrow (BM) and peripheral blood (PB). PHOX2B has been identified as a sensitive and specific MRD marker; however, its expression varies between tumors. Therefore, a panel of markers could increase sensitivity. METHODS To ident...
متن کاملDetecting minimal residual disease in neuroblastoma: still a ways to go.
Neuroblastoma is the most common extracranial solid tumor of childhood and accounts for 10% of all cancers in children. The development of neuroblastoma involves both embryonic and tumorigenic factors, making the tumor very heterogeneous both biologically and clinically. Neuroblastoma tumors originate from embryonic neural crest cells committed to the development of the sympathetic nervous syst...
متن کاملExploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma.
PURPOSE Minimal residual disease (MRD) presents a significant hurdle to curing metastatic neuroblastoma. Biological therapies directed against MRD can improve outcome. Evaluating treatment efficacy requires MRD measurement, which serves as surrogate endpoint. Because of tumor heterogeneity, no single marker will likely be adequate. Genome-wide expression profiling can uncover potential MRD mark...
متن کاملMolecular Markers in Neuroblastoma
Neuroblastoma, one of the common malignant childhood tumors, arises from neuroblast cells derived from theneural crest and destined for the adrenal medulla and the sympathetic nervous system and shows remarkable biologicalheterogeneity, resulting in favorable or unfavorable outcomes. Some tumors make rapid progress with a fataloutcome. In other instances, the tumors regress spontaneously in inf...
متن کاملMethylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma.
PURPOSE PCR-based detection of minimal residual disease (MRD) in neuroblastoma (NB) is presently based on NB-specific transcripts. However, the expression of these targets varies between patients and upon treatment, and only PHOX2B is truly specific. RASSF1a is methylated (RASSF1a(M)) in NB, and we investigated whether it can serve as a specific and stable DNA MRD marker. PATIENTS AND METHODS...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Biological and Pharmaceutical Bulletin
سال: 2008
ISSN: 0918-6158,1347-5215
DOI: 10.1248/bpb.31.1071